For the Current Quarter, the growth estimate for The Chemours Company is 203.7%, while for the Next Quarter the stock growth estimate is 50.8%. The average EPS estimate of 2 Wall Street analysts is $0.80 per share, compared to the company’s reported EPS of $0.27 per share in the year-ago quarter. The company’s market cap is $7.76 Billion, and the average volume is 2.4 Million. The company’s 5 year Earnings per share growth and Capital Spending growth remains at -65.59 and -0.98. Ropes Wealth Advisors LLC now owns 3,099 shares of the specialty chemicals company’s stock worth $119,000 after buying an additional 1,400 shares in the last quarter. Jefferies Group LLC upgraded shares of Chemours from a hold rating to a buy rating and increased their price objective for the company from $35.00 to $48.00 in a research report on Wednesday, March 29th. BlackRock Inc. now owns 19,160,930 shares of the specialty chemicals company’s stock valued at $737,696,000 after buying an additional 19,121,339 shares during the period. Citigroup Inc upgraded Chemours from a “neutral” rating to a “positive” rating and increased their price objective for the stock from $26.00 to $40.00 in a research report on Friday, February 17th. Hedge funds and other institutional investors own 74.71% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Stock Observer and is owned by of Stock Observer. Currently, the stock has a 1 Year Price Target of $47. FMR LLC raised its position in Chemours by 481.3% in the fourth quarter. The Chemours Company (CC) has gained $2.69, or +6.86%, in the last 30 days.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 15th. Chemours presently has a consensus rating of “Buy” and a consensus price target of $37.70. Strid Group LLC purchased a new position in shares of Chemours during the third quarter valued at about $186,000. Norges Bank purchased a new position in shares of Chemours during the fourth quarter valued at $196,709,000.
Many analysts have provided their estimated foresights on The Chemours Company Earnings, with 7 analysts believing the company would generate an Average Estimate of $0.82.
Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for The Chemours Company the EPS stands at 0.75 for the previous quarter, while the analysts predicted the EPS of the stock to be 0.5, suggesting the stock exceeded the analysts’ expectations. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Investors of record on Wednesday, May 17th will be issued a dividend of $0.03 per share.
The Chemours Company was covered by a number of analysts recently, 2 rated the stock as Buy, 1 rated Hold, 1 rated sell and 0 gave an Underperform. The ex-dividend date of this dividend is Monday, May 15th. This represents a $0.12 annualized dividend and a dividend yield of 0.29%. Nationwide Fund Advisors increased its position in Chemours by 262.6% in the first quarter. If you are reading this article on another publication, it was stolen and reposted in violation of U.S. & worldwide copyright and trademark laws. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/05/27/chemours-co-cc-pt-raised-to-55-00-updated.html.
CC has been the subject of several recent analyst reports. BlackRock Institutional Trust Company N.A. now owns 4,613,843 shares of the specialty chemicals company’s stock worth $73,821,000 after buying an additional 31,548 shares in the last quarter.
The Chemours Company (CC) belongs to the “Basic Materials” sector with an industry focus on “Specialty Chemicals”, with Mr. Mark P. Vergnano as Chief Exec. Officer, Pres and Director.
In other Chemours news, VP Erich Parker sold 4,908 shares of the firm’s stock in a transaction dated Tuesday, May 16th. Chemours’s dividend payout ratio is now 14.81%. The shares were sold at an average price of $39.83, for a total value of $907,367.23. The disclosure for this sale can be found here. The Firm operates through three divisions: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2).
Hedge funds have recently made changes to their positions in the stock. The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
